MCID: PDG002
MIFTS: 27

Pdgfrb-Associated Chronic Eosinophilic Leukemia

Categories: Cancer diseases, Immune diseases, Liver diseases, Rare diseases

Aliases & Classifications for Pdgfrb-Associated Chronic Eosinophilic Leukemia

MalaCards integrated aliases for Pdgfrb-Associated Chronic Eosinophilic Leukemia:

Name: Pdgfrb-Associated Chronic Eosinophilic Leukemia 52 25 71
Atypical Philadelphia-Negative Chronic Myeloid Leukemia 52 25
Primary Eosinophilia with Chronic Myeloproliferative Disorder 25
Clonal Eosinophilia with Chronic Myeloproliferative Disorder 25
Chronic Myeloproliferative Disorder with Eosinophilia 25
Leukemia, Myelomonocytic, Chronic 71
Chronic Myelomonocytic Leukemia 25

Classifications:



External Ids:

UMLS 71 C0023480 C3711560

Summaries for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Genetics Home Reference : 25 PDGFRB-associated chronic eosinophilic leukemia is a type of cancer of blood-forming cells. It is characterized by an elevated number of white blood cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRB-associated chronic eosinophilic leukemia. Some people with this condition have an increased number of other types of white blood cells, such as neutrophils or mast cells, in addition to eosinophils. People with this condition can have an enlarged spleen (splenomegaly) or enlarged liver (hepatomegaly). Some affected individuals develop skin rashes, likely as a result of an abnormal immune response due to the increased number of eosinophils. PDGFRB PDGFRB

MalaCards based summary : Pdgfrb-Associated Chronic Eosinophilic Leukemia, also known as atypical philadelphia-negative chronic myeloid leukemia, is related to chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, and has symptoms including fatigue, fever and night sweats. The drugs Cefepime and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow.

Related Diseases for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Diseases related to Pdgfrb-Associated Chronic Eosinophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
# Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 13.1
2 juvenile myelomonocytic leukemia 12.3
3 myelodysplastic/myeloproliferative neoplasm 11.9
4 myelodysplastic syndrome 11.9
5 leukemia 11.2
6 leukemia, acute myeloid 10.9
7 myeloid leukemia 10.8
8 acute leukemia 10.7
9 splenomegaly 10.7
10 thrombocytopenia 10.7
11 myeloproliferative neoplasm 10.7
12 refractory anemia 10.6
13 chromosomal triplication 10.6
14 myelofibrosis 10.6
15 leukemia, chronic myeloid 10.6
16 vasculitis 10.5
17 hypereosinophilic syndrome 10.5
18 neutropenia 10.5
19 systemic mastocytosis 10.5
20 mastocytosis 10.5
21 pancytopenia 10.4
22 graft-versus-host disease 10.4
23 atypical chronic myeloid leukemia 10.4
24 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.4
25 purpura 10.4
26 acute graft versus host disease 10.4
27 leukemia, chronic lymphocytic 10.3
28 polycythemia vera 10.3
29 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.3
30 deficiency anemia 10.3
31 histiocytosis 10.3
32 polycythemia 10.3
33 monocytic leukemia 10.3
34 dendritic cell tumor 10.3
35 myelodysplastic syndrome with excess blasts 10.3
36 chronic neutrophilic leukemia 10.3
37 respiratory failure 10.3
38 thrombocytosis 10.3
39 myeloma, multiple 10.3
40 lymphoma 10.3
41 chronic leukemia 10.3
42 sarcoma 10.3
43 essential thrombocythemia 10.3
44 acute kidney failure 10.3
45 spindle cell sarcoma 10.3
46 47,xyy 10.3
47 blastic plasmacytoid dendritic cell 10.3
48 temporal arteritis 10.2
49 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
50 leukemia, acute lymphoblastic 10.2

Graphical network of the top 20 diseases related to Pdgfrb-Associated Chronic Eosinophilic Leukemia:



Diseases related to Pdgfrb-Associated Chronic Eosinophilic Leukemia

Symptoms & Phenotypes for Pdgfrb-Associated Chronic Eosinophilic Leukemia

UMLS symptoms related to Pdgfrb-Associated Chronic Eosinophilic Leukemia:


fatigue, fever, night sweats

Drugs & Therapeutics for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Drugs for Pdgfrb-Associated Chronic Eosinophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 330)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Mercaptopurine Approved Phase 3 50-44-2 667490
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
6
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
7
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
8
Idarubicin Approved Phase 3 58957-92-9 42890
9
Thioguanine Approved Phase 3 154-42-7 2723601
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
12
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
13
Dalteparin Approved Phase 3 9005-49-6
14
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
15
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
16
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
17
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
18
Acyclovir Approved Phase 3 59277-89-3 2022
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
21
Lenalidomide Approved Phase 3 191732-72-6 216326
22
Daunorubicin Approved Phase 3 20830-81-3 30323
23
Hydroxyurea Approved Phase 3 127-07-1 3657
24
tannic acid Approved Phase 3 1401-55-4
25
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
26
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
27
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
28
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
29
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
30
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
31
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
32
Polyestradiol phosphate Approved Phase 3 28014-46-2
33
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
34
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
35
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37 Guadecitabine Investigational Phase 3 929901-49-5
38
Lonafarnib Investigational Phase 3 193275-84-2 148195
39 Anesthetics, Dissociative Phase 3
40 Analgesics, Non-Narcotic Phase 3
41 Interleukin-2 Phase 3
42 Analgesics Phase 3
43 Anti-HIV Agents Phase 3
44 Anti-Retroviral Agents Phase 3
45 Neurotransmitter Agents Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47 Anti-Anxiety Agents Phase 3
48 Psychotropic Drugs Phase 3
49 Antipsychotic Agents Phase 3
50 Cola Phase 3

Interventional clinical trials:

(show top 50) (show all 477)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
3 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
5 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
8 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
9 A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study) Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
10 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
11 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
12 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
13 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
14 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
15 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
16 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
17 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
18 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
19 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
20 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
21 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
22 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
23 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
24 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
25 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
26 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
27 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
28 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
29 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
30 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
31 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
32 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Recruiting NCT04266301 Phase 3 MBG453;Azacitidine;Placebo
34 The Clinical Efficacy of Azacytidine Combined With HAG Regimen in Elderly Patients With Myeloid Malignancy Recruiting NCT03873311 Phase 3 Azacytidine, HAG Regimen
35 A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Recruiting NCT04256317 Phase 2, Phase 3 Azacitidine;ASTX030 (cedazuridine + azacitidine);Cedazuridine
36 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
37 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Active, not recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
38 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
39 A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents Active, not recruiting NCT02907359 Phase 3 Guadecitabine
40 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
41 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
42 A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML) Active, not recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
43 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
44 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
45 A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia Terminated NCT00109538 Phase 3 Lonafarnib
46 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
47 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
48 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
49 A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
50 A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) Unknown status NCT03040401 Phase 1, Phase 2 Cohort 1, Ceplene® and Proleukin®;Cohort 2, Ceplene® and Proleukin®;Cohort 3, Ceplene® and Proleukin®

Search NIH Clinical Center for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Genetic Tests for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Anatomical Context for Pdgfrb-Associated Chronic Eosinophilic Leukemia

MalaCards organs/tissues related to Pdgfrb-Associated Chronic Eosinophilic Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, Liver, Neutrophil, Spleen

Publications for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Articles related to Pdgfrb-Associated Chronic Eosinophilic Leukemia:

# Title Authors PMID Year
1
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. 61
15087377 2004

Variations for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Expression for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Search GEO for disease gene expression data for Pdgfrb-Associated Chronic Eosinophilic Leukemia.

Pathways for Pdgfrb-Associated Chronic Eosinophilic Leukemia

GO Terms for Pdgfrb-Associated Chronic Eosinophilic Leukemia

Sources for Pdgfrb-Associated Chronic Eosinophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....